| Literature DB >> 33624399 |
Jesse L Berry1,2, Francis L Munier3, Brenda L Gallie4,5,6, Ashley Polski1,2, Sona Shah1,2, Carol L Shields7, Dan S Gombos8, Kathleen Ruchalski9, Christina Stathopoulos3, Rachana Shah10, Rima Jubran10, Jonathan W Kim1,2, Prithvi Mruthyunjaya11, Brian P Marr12, Matthew W Wilson13,14, Rachel C Brennan15, Guillermo L Chantada16,17,18, Murali M Chintagumpala19, A Linn Murphree1,2.
Abstract
Standardized guidelines for assessing tumor response to therapy are essential for designing and conducting clinical trials. The Response Evaluation Criteria In Solid Tumors (RECIST) provide radiological standards for assessment of solid tumors. However, no such guidelines exist for the evaluation of intraocular cancer, and ocular oncology clinical trials have largely relied on indirect measures of therapeutic response-such as progression-free survival-to evaluate the efficacy of treatment agents. Herein, we propose specific criteria for evaluating treatment response of retinoblastoma, the most common pediatric intraocular cancer, and emphasize a multimodal imaging approach for comprehensive assessment of retinoblastoma tumors in clinical trials.Entities:
Keywords: clinical trials; imaging; ocular oncology; response criteria; retinoblastoma; ultrasonography
Year: 2021 PMID： 33624399 PMCID： PMC8049511 DOI： 10.1002/pbc.28964
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN： 1545-5009 Impact factor: 3.167